Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Non-Randomised, 2-Period, Single Centre Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily.

Next Previous
Search
Trial Profile

An Open-Label, Non-Randomised, 2-Period, Single Centre Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fostamatinib (Primary) ; Digoxin
  • Indications Arrhythmias; B-cell lymphoma; Chronic lymphocytic leukaemia; Idiopathic thrombocytopenic purpura; Ischaemic heart disorders; Rheumatoid arthritis; Solid tumours; T-cell lymphoma; Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

    • Most Recent Events

    • 26 Oct 2015 Results published in the Clinical Therapeutics
    • 05 Oct 2011 Actual end date (September 2011) added as reported by ClinicalTrials.gov.
    • 05 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top